ClinicalTrials.gg
Enrolling by invitationNCT04064008Updated Nov 14, 2023

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Z Revision Femoral Stems

An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Enrolling by invitation at 1 site in Poland. Per ClinicalTrials.gov, last updated 2023-11-14.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.

Planned enrollment
16th of 20
30 · median 69
Started
2019
with 2 others
Observational
20 of 21
5 open now
Primary completion
2030-04
later than 6 of 12 live
Registered
16th of 21
by date

Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 16th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2019, is one of 20 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 16th registered.

Joint Diseases

386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.

Browse Joint Diseases studies →

Open to participants now

5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Joint Diseases by MicroPort Scientific Corporation, or all of them as a file.
02

Study summary

Single center, prospective follow-up of previously implanted subjects

Read the detailed description

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Z Revision Femoral Stems

03

Conditions studied

  • Joint Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has undergone a revision for nonunion and/or hardware removal (i.e. all conditions resulting in poor quality proximal bone).
  2. Subject is implanted with the PROFEMUR® Z Revision Femoral Stem at the time of their revision THA.
  3. Subject is willing and able to complete required study visits or assessments.
  4. Plans to be available through the 10 year postoperative follow-up visit.

Previously implanted bilateral subjects can have both THAs enrolled in the study provided:

  1. the PROFEMUR Z Revision Femoral Stem was implanted in both,
  2. all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  4. the subject agrees to a second document specific to the second THA. Prospective enrollment of a previously unimplanted hip is not permitted in this study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol.
  2. Subject has a PROFEMUR Neck Varus/Valgus CoCr 8 Degree, Part number PHAC 1254 implanted in the enrolled THA.
  3. Has or had an overt infection at the time of implantation.
  4. Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation.
  5. Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation.
  6. Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable.
  7. Subjects unwilling to sign the document.
  8. Subjects with substance abuse issues.
  9. Subjects with an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study.
  10. Subjects who are incarcerated or have pending incarceration.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary Total Hip Arthroplasty

    Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem

    Device: PROFEMUR® Z Revision Femoral Stem

Interventions

  • DevicePROFEMUR® Z Revision Femoral Stem

    Total Hip Total Hip Arthroscopy

06

What researchers measure

Primary outcomes

  1. Survivorship of ProFemur Z Stem out to 10 years

    Kaplan-Meier survivorship at specific intervals out to 10 years follow up

    Time frame: 10 years.

Secondary outcomes

  1. Revision rate of the Profemur Z stem out to 10 years

    Cummulative revision rate at early (2-5yrs), midterm (5-7 year) and long-term (10 year) follow up.

    Time frame: 2-5 years, 5-7 years, and 10 years.

  2. to characterize total functional scores for subjects, as assessed by Oxford Hip Scores

    The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'.

    Time frame: 2-5 years, 5-7 years, and 10 years.

Other outcomes

  1. to characterize total functional scores for subjects, as assessed by EQ-5D-3L scores.

    EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems.

    Time frame: 2-5 years, 5-7 years, and 10 years.

07

Study locations

1 site
  • Samodzielny Publiczny Szpital Kliniczny Klinika
    Otwock, 05-400, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2019 (actual). Primary completion is estimated for Apr 2030, 132 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2019
First posted
Aug 21, 2019
StartActual
Apr 4, 2019
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2030
Last update
Nov 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04064008
Responsible party
Sponsor
First posted
Aug 21, 2019
Start date
Apr 4, 2019
Primary completion
Apr 2030 (estimated)
Completion
Apr 2030 (estimated)
Last update
Nov 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion